register

News & Trends - Pharmaceuticals

Precision prescribing to combat Australia’s expected surge in mental illness

Health Industry Hub | July 15, 2020 |

Pharma News: COVID-19 social isolation, familial and community disconnection, shock, job loss and health fears create the perfect storm for a person who is vulnerable to mental illness. 

1 million Australians suffer from depression in any one year.

New modelling by the University of Sydney’s Brain and Mind Centre confirms our fears, that the COVID-19 pandemic may see more deaths by suicide than by the virus itself. Predictions estimate a 25% increase to suicide rates and even higher rates for younger Australians.

In a recent submission to the Australian Department of Health, myDNA outlined how precision prescribing and pharmacogenomics could be a a new, and vitally important, dimension in the fight against such a shocking tidal wave of suicide and depression.

Specialists or GPs employ a level of guess work when recommending which anti-depressant treatment will work the first time. Studies show, 50% of the time, it will take three or more attempts of prescribing yet another medicine before the right treatment finally settles for that patient. This is because, when it comes to mental health, our genes run interference with how we react to medication.

Australian-based company, myDNA, has researched and developed a new way of determining the best antidepressant treatment for patients suffering from mental health disorders. This is achieved through a genetic test that can reveal a person’s ability to processes and metabolise certain medications. Known as Pharmacogenomics, this test is converted into vital knowledge for a doctor, who can then be certain that the medication they prescribe is personalised and accurate – the first time.

This type of test is now used by Australia’s leading pathology services providing such tests for doctors and support services in pharmacies across the country. 

Amid fears that this pandemic could spawn a ‘generational mental health crisis,’ pharmacogenomics and with it, precision prescribing, have an important role to play in protecting those Australians struggling with mental illness. 


News & Trends - MedTech & Diagnostics

$54 million cancer centre opens in one of Australia’s fastest growing communities

Health Industry Hub | March 28, 2024 |

MedTech & Diagnostics News: Cancer care provider, GenesisCare, is now treating patients at a new $54 million integrated cancer centre […]

More


Marketing & Strategy

Bayer, MSD and Takeda among winners at Asia Pacific awards

Bayer, MSD and Takeda among winners at Asia Pacific awards

Health Industry Hub | March 28, 2024 |

Bayer, MSD, Takeda, Alcon, and Cipla emerge as winners among this week’s announcements of Asia Pacific awards which celebrate organisations […]

More


News & Trends - MedTech & Diagnostics

Queensland elevates diagnostic precision with cutting-edge imaging technology

Queensland elevates diagnostic precision with cutting-edge imaging technology

Health Industry Hub | March 28, 2024 |

MedTech & Diagnostics News: Mackay Base Hospital and Qscan Mackay have unveiled state-of-the-art medical imaging machines to elevate patient care […]

More


News & Trends - Pharmaceuticals

Landmark collaboration sparks inauguration of precision care clinic

Landmark collaboration sparks inauguration of precision care clinic

Health Industry Hub | March 28, 2024 |

Pharma News: In a landmark collaboration, Australians with cancer will receive more personalised care through the newly established Precision Care […]

More


This content is copyright protected. Please subscribe to gain access.